 |
|
||||||
|
|
Newsletters
Spring 2013 Volume 9, Issue 6 Special Gala Report Volume 9, Issue 5 Winter 2012/2013 Volume 9, Issue 4 Fall 2012 Volume 9, Issue 3 Summer 2012 Volume 9, Issue 2 Spring 2012 Volume 9, Issue 1 MYELOMA TODAY – Special Gala Report Volume 8, Issue 11 Winter 2011 Volume 8, Issue 10 Fall 2011 Volume 8, Issue 9 Summer2011 Volume 8, Issue 8 Spring 2011 Volume 8, Issue 7 Special Gala Report Volume 8, Issue 6 Winter 2010 Volume 8, Issue 5 Fall 2010 Volume 8, Issue 4 Summer 2010 Volume 8, Issue 3 Spring 2010 Volume 8, Issue 2 Fall/Winter 2009/2010 Volume 8, Issue 1 Summer 2009 Volume 7, Issue 10 Spring 2009 Volume 7, Issue 9 Fall 2008 Volume 7, Issue 8 Summer 2008 Volume 7, Issue 7 Spring 2008 Volume 7, Issue 6 Winter 2008 Volume 7, Issue 5 Fall 2007 Volume 7, Issue 4 Summer 2007 Volume 7, Issue 3 Spring 2007 Volume 7, Issue 2 Winter 2006 Volume 7, Issue 1 Fall 2006 Volume 6, Issue 10 Summer 2006 Volume 6, Issue 9 Spring 2006 Volume 6, Issue 8 Winter 2005/2006 Volume 6, Issue 7 Fall 2005 Volume 6, Issue 6 Summer 2005 Volume 6, Issue 5 Spring 2005 Volume 6, Issue 4 Winter 2004/2005 Volume 6, Issue 3 Spring 2004 Volume 5, Issue 10 Winter 2003/2004 Volume 5, Issue 9 October 2003 Volume 5, Issue 8 August 2003 Volume 5, Issue 7 June 2003 Volume 5, Issue 6 February 2003 Volume 5, Issue 5 Winter 2002/2003 Volume 5, Issue 4 October 2002 Volume 5, Issue 3 August 2002 Volume 5, Issue 2 Special Edition - June 2002 Volume 4, Issue 11 April 2002 Volume 4, Issue 10 February 2002 Volume 4, Issue 9 Winter 2001/2002 Volume 4, Issue 8 Summer 1997 Volume 2, Issue 7 Spring 2013 Volume 9, Issue 6
Articles include:
Special Gala Report Volume 9, Issue 5 On Saturday, October 27, 2012, nearly 1,200 guests gathered at the Wilshire Ebell Theatre in Los Angeles in support of the IMF’s 6th Annual Comedy Celebration. Save the date for this year's Comedy Celebration! Winter 2012/2013 Volume 9, Issue 4 Myeloma Today Winter 2012/2013 Articles include:
Fall 2012 Volume 9, Issue 3 Articles include:
Summer 2012 Volume 9, Issue 2 Articles include:
Spring 2012 Volume 9, Issue 1 Articles include:
MYELOMA TODAY – Special Gala Report Volume 8, Issue 11 A special edition packed with photos from the event. If you were there, or if you couldn't make it, you will want to see this. Winter 2011 Volume 8, Issue 10
Articles include: Fall 2011 Volume 8, Issue 9
Articles include: Summer2011 Volume 8, Issue 8
Articles include: Spring 2011 Volume 8, Issue 7
Articles include: Special Gala Report Volume 8, Issue 6 MYELOMA TODAY – Special Gala Report 4th Annual Comedy Celebration Benefiting the Peter Boyle Memorial Fund Winter 2010 Volume 8, Issue 5
Articles include: Fall 2010 Volume 8, Issue 4 Myeloma Today Fall 2010 in PDF format
Articles include: Summer 2010 Volume 8, Issue 3
Articles include: Spring 2010 Volume 8, Issue 2
Articles include: Fall/Winter 2009/2010 Volume 8, Issue 1 Myeloma Today Fall/Winter 2009/2010 + Special Gala Supplement
Articles include: Summer 2009 Volume 7, Issue 10
Articles include: Spring 2009 Volume 7, Issue 9 Myeloma Today Spring 2009 in PDF
Articles include: Myeloma Today Spring 2009 in PDF
Articles include: Fall 2008 Volume 7, Issue 8 Myeloma Today Fall 2008 in PDF
Articles include: Summer 2008 Volume 7, Issue 7 Myeloma Today Summer 2008 in PDF
Articles include: Spring 2008 Volume 7, Issue 6 Myeloma Today Spring 2008 in PDF
Articles include: Winter 2008 Volume 7, Issue 5 Myeloma Today Winter 2007 in PDF
Articles include: Fall 2007 Volume 7, Issue 4 Myeloma Today Fall 2007 in PDF Articles include:
Summer 2007 Volume 7, Issue 3 Myeloma Today Summer 2007 in PDF format Articles include:
Spring 2007 Volume 7, Issue 2 Myeloma Today Spring 2007 in PDF format Articles include:
Winter 2006 Volume 7, Issue 1 Winter 2006 Myeloma Today in PDF Articles include:
Fall 2006 Volume 6, Issue 10 Fall 2006 Myeloma Today in PDF Articles include:
Summer 2006 Volume 6, Issue 9 Summer 2006 Myeloma Today in PDF Articles include:
Spring 2006 Volume 6, Issue 8 Spring 2006 Myeloma Today in PDF Articles include:
Winter 2005/2006 Volume 6, Issue 7 IMF's Centers for Disease Control and Prevention (CDC) grant renewed for second year With our CDC grant renewal for 2006, the IMF will reach out to additional communities, as well as strengthen the community relationships we formed in 2005. Advocacy Update: Support for Cancer Priorities Short-Changed in President’s Budget President Bush’s recent state-of-the-union speech set the stage for an annual federal spending proposal that threatens to further erode our nation’s long-standing commitment to advance the pace of medical research and drug access. The Yin and Yang of Long-Term Survivorship Philosophers in the Han dynasty (207 BCE to 9 AD) developed the concept of Yin and Yang, the idea that everything in the universe has its opposite. If this is so, where does cancer fit into this ancient method of understanding life? American Society of Hematology - 47th Annual Meeting Recap from the American Society of Hematology's 47th annual meeting held in Atlanta, Georgia on December 10–14, 2005. We have selected the major myeloma presentations for you to keep informed on the latest myeloma research that was presented. 2006! Another new year, one filled with new opportunities, new partnerships, and renewed hope. As is customary it's also a time to look back on what we've achieved and this year I'm especially proud of what the IMF has accomplished. The Stafford Family Funds Myeloma Research Grant To date, the four WAMP swim-a-thon events have raised more than $40,000—enough to fund a grant in my dad's honor through the IMF research program. Our family plans to continue our efforts to help fund myeloma research in hopes for a cure for my On August 13, 2005, Flavia and her friends transformed the boardroom and mezzanine of Luxe Hotel Rodeo Drive in Beverly Hills into a fabulous fashion trunk show to benefit the IMF's myeloma research program. Shop For A Cure featured Flavia's own clot 2006 IMF Brian D. Novis Research Grant Awards Grant Recipients Honored at IMF Scientific Advisors Meeting. Combination Therapy with VELCADE plus Melphalan & Prednisone At the 2005 annual meeting of the American Society of Hematology, Dr. Jesús F. San Miguel presented interim data on the ongoing GEM/PETHEMA study of VELCADE® (bortezomib) plus melphalan and prednisone (V-MP) in elderly, previous It's important to know that you can lead a good life—and a long one—even with myeloma. Board of Directors Profile: Matthew Robinson This is a very exciting growth period for the Foundation. And it's enormously rewarding for me to apply my business experience of the last 20 years to helping the IMF accomplish its goals and objectives.
IMFers MAKE A DIFFERENCE! When the IMF started its member fundraising program several years ago, we had no idea how our members would respond. Would they be intimidated? After all, "fundraising" is a daunting word to some of us. Or would the opportunity of being pro As the IMF embarks on a new year, it serves well to look back at the accomplishments of 2005. It was an exciting year. Robin Tuohy, Kelly Cox, and I made visits to about a third of the myeloma support groups around the country. This was a very reward The IMF Returns to St. Petersburg, Russia International Clinical Conference Promotes Myeloma Education IMF Hotline Coordinators Answer Your Questions My brother was just told he has a very rare form of myeloma called IgM. I can’t find anything on it and keep coming across discussions of something called “Waldenström’s macroglobulinemia.” Can you help? Fall 2005 Volume 6, Issue 6 The IMF, along with researchers, physicians, patients, and industry leaders, is extremely excited as we prepare for the annual American Society of Hematology (ASH) meeting, this year being held in Atlanta, Georgia on December 10th through 13th. The I Patient Perspectives: NUMBERS DON'T LIE, or do they? In the business world we're often told that Figures Don't Lie, but that Liars Can Figure. While that may be true in some scandalous incidents of corporate wrongdoing, we who are cancer advocates also know that while medical statistics don't lie, that IMF Around the Globe: Israeli Association of Myeloma Patients The Israeli Association of Myeloma Patients, also known as AMEN, was founded to benefit the welfare of myeloma patients in Israel. Sixth Annual Support Group Leader Retreat The word "Retreat" is defined in various ways: (1) an act or process of withdrawing especially from what is difficult or dangerous, and also (2) a period of group withdrawal for meditation, study, and instruction under a director. Well, I would have Making Clinical Trials More Patient-Friendly All new cancer drugs must be proven safe and effective in clinical trials before they can be made available to patients. At the 2005 IMF Support Group Leader Retreat, IMFer and leader of the Manhattan and White Plains (New York) myeloma support group Pathogenesis and Maintenance of Multiple Myeloma Recent studies in my laboratory have identified a novel pathway promoting enhanced survival of chronic B cell malignancies. We demonstrated that B lymphocyte stimulator (BLyS), a member of the tumor necrosis factor family, was expressed in an autocri MOZOBIL™, a potential new agent for Stem Cell Harvesting Colony-stimulating factors such as G-CSF (filgrastim) induce the marrow to grow, while MOZOBIL is a new agent that aids in releasing stem cells into circulating blood where they can be collected by a process called apheresis. Patient Experience: One Day at a Time...for 18 Years The most powerful tool in a cancer patient's arsenal is the mind—when your body is beaten down physically, you can push your mind to keep you strong mentally while you face the challenges life has given you. Education, Advocacy, and Awareness: Profile of Robin Tuohy My family's journey through cancer began in September of 2000. My husband, Michael, and I were enjoying a family vacation with our children, Allison and Mikey, then ages 7 and 2. On one of the "kiddie" rides at Santa's Village, Michael experienced ex IMF Hotline Coordinators Answer Your Questions I have been diagnosed with a solitary plasmacytoma of the bone. What is it? And what is the likelihood that I will develop multiple myeloma? The Multiple Myeloma ListServe The Multiple Myeloma ListServ—affectionately called "The List" by its 1500 members—was founded by Michael Katz, an IMF Director, and June Brazil, a myeloma patient. At a time when the number of in-person myeloma support groups was nowhere IMF Around the Globe: The Greater Montreal Multiple Myeloma Support Group As The Greater Montreal Multiple Myeloma Support Group approaches its first anniversary, it is encouraging to review the progress that the group has made since our first meeting in November 2004. Member Events: Gary C. Heuer, Jr. Memorial Golf Tournament 140 golfers started out the day’s activities with breakfast at Craigie Brae Golf Course in N. Chili, NY. Following the exciting 18-hole tournament, the event’s participants gathered for a chicken barbecue at Freeman Park in Mumford, NY. Fundraising: Rocking in Rhode Island Our mother, Carol Murray-Rossi, was diagnosed with multiple myeloma in 2003. But her personal struggle with this disease did not stop her from looking for ways to reach out and help others fighting myeloma. Fundraising: Katie's Birthday Charity Bash As Katie's birthday approached, she came to me with an idea of how she wanted to celebrate. In lieu of birthday gifts, Katie asked her friends to honor her grandmother by donating money to help cancer patients. South Florida's Dynamic Duo: Cindy Feltzin and Vicki Anderson Ferraro Every support group has a personality. Our group is a family. We want everyone who joins us to feel welcome, to feel safe, and to feel very hopeful. IMF Board Member Interview with Benson and Carol Klein Since being diagnosed, I have a different outlook. I used to worry about the little things. Now, I only think about the big picture. Insights into New Myeloma Tx: Revlimid Study Tops List of Investigations that may Benefit Patients Recently, the Myeloma Program at New York-Presbyterian Hospital/Weill Cornell Medical Center has generated a considerable amount of excitement by launching a study evaluating a combination regimen, known as BiRD, that includes the antibiotic Biaxin&r Member Events: 4th Annual MMAMM Benefit Keeps Lee Grayson's Memory Alive Lee, who never had children, or a hit song, or huge record deal, worried that his life would leave no mark on the planet. But those who knew him, and even those who never had the blessing of knowing him, feel his presence each year at MMAMM. "Ask any Summer 2005 Volume 6, Issue 5
Education, Advocacy, and Awareness: The seminar inspired me so much that starting a myeloma support group in my area is now one of my top priorities. With newly found hope, education, and knowledge of the IMF's passion for finding a cure, we feel more in control of our situation.
Education, Advocacy, and Awareness: When truth meets politics to collaborate for change, great things can happen for future generations. Meet the IMF: Allan Weinstein Joins the IMF Board of Directors I was diagnosed around September of 2002. I had a symptom but it wasn’t a typical myeloma symptom. I was treated for an infection, but the infection recurred, and my internist didn’t like that. The IMF Welcomes David Siegel, MD, PhD The IMF is pleased to announce that Dr. David Siegel has joined its Scientific Advisory Board. IMF Hotline Coordinators Answer Your Questions My father-in-law has myeloma and may be a candidate for a stem cell transplant. I am pregnant. Can my baby’s umbilical cord blood be used for his transplant? The International Myeloma Foundation’s CDC Initiative The IMF is thrilled to have received a grant from the CDC to help in their efforts to increase awareness among African Americans regarding hematologic malignancies. Revlimid® (Lenalinomide): Where Do We Stand? One way or another, it seems that the long wait for Revlimid may be nearing an end. IMF Honors Kenneth C. Anderson, MD with 2005 Robert A. Kyle Lifetime Achievement Award Dr. Anderson has done more for the field of multiple myeloma and related disorders than anyone else. He is most deserving of this Lifetime Achievement Award. Myeloma stem Cells: Attacking the Disease at its Source Our research focuses on studying the originating cell in myeloma (the myeloma stem cell) and developing treatments that target this cell and inhibit the production of new tumor cells. I have just returned from a very successful meeting in Stockholm, Sweden, where exciting updates on myeloma research and treatments were presented. Patient Perspective: Cancer Etiquette The question most commonly asked of a patient is, “How are you?” There is inherently nothing wrong with such a question. But is it the standard “How are you?” we routinely ask when we aren’t really interested in the answer? Is it the mundane “How are Patient Perspective: Tracking My Numbers My MGUS was found as a fluke during an annual physical in May, 1993. My total serum protein was slightly above the top of the normal range for that test and soon went back to normal. Otherwise, I still would not know that I have MGUS since I am still Update on Lenalidomide (CC-5013; Revlimid®) There has been intense research to develop a safer and more effective version of thalidomide. Lenalidomide (CC-5013; Revlimid®) is the first analog (close cousin) of thalidomide to enter clinical trials. It may prove to be more effective and safe Supportive Care: Erectile Dysfunction - Current Treatment Options
Erectile dysfunction (ED) is a very common disorder that affects up to half the male population over the age of 40. IMF Hotline Coordinators Answer Your Questions What is the difference between the terms "myeloma" and "multiple myeloma?" "My grandmother died of multiple myeloma and now my dad has been diagnosed with this disease. Is myeloma hereditary?"
There are a number of factors that are likely to increase your comfort with a medical test. Susan J. Leclair, PhD, CLS (NCA)helps you understand why a test has been ordered for you, how it will be conducted, and what the reference ranges are. Community Goals Lead to Results Are you more interested in myeloma research or cancer research? Is there a difference? What about other issues, like drug coverage and payments for PET scans? Can myeloma issues be separated from cancer issues in general? Sorority Raises Funds for a Cure During the summer of 2004, my father was diagnosed with multiple myeloma. Myeloma? I had never heard of this disease. And I was not alone. Did You Know: What Causes Hyperviscosity in Multiple Myeloma? Viscosity is the property of fluid to resist flow. In myeloma patients, hyperviscosity (increased serum viscosity) results from increased levels of circulating serum immunoglobulins. Winter 2004/2005 Volume 6, Issue 3 Advocacy Update: Federal Support for Cancer Issues in Decline The science of cancer research holds unprecedented promise. Unfortunately, the issues of federal funding dominating the political agenda—for cancer research and drugs and treatments through Medicare—are not addressing this opportunity. ASH 2004: The Avalanche of Information Continues The recent ASH meeting in San Diego included a huge amount of information relevant to myeloma. New Developments in Multiple Myeloma Dr. Morie Gertz of the Mayo Clinic brings up to date on new developments in treatment and supportive care. The Expanding Role of Proteasome Inhibition in Multiple Myeloma At the 2004 ASH meeting, data from a variety of proteasome inhibitor studies was discussed. Based on these, it seems safe to conclude that more patients with relapsed or refractory disease will benefit from such therapy than previously thought.
IMFer Profile: Andy Lebkuecher Like most people who find out one day that they or a loved one has myeloma, we’d never heard of it before. I said, “OK, I guess we need to learn about this.”...We attended an IMF Patient & Family Seminar and became very involved with the Foundation. Spring 2004 Volume 5, Issue 10
Los Angeles Area Support Group Salutes Leader
On behalf of the International Myeloma Foundation, I would like to thank you for your support and update you on our progress with the IMF’s research project, Bank On A Cure®. Treating Multiple Myeloma: The Little Rock Approach Peripheral blood stem cell (PBSC)-supported high-dose melphalan 200 mg/m2 is now considered standard therapy for patients with symptomatic or progressive myeloma. During the last five years, additional new agents effecting salvage rates of 30% - 50% The Genetics of Multiple Myeloma Extensive genetic lesions, both at the chromosome and gene levels, characterize malignant plasma cells. Although most patients present with a large number of malignant plasma cells at diagnosis (up to 1,000 billion malignant cells), chromosomal analy Drug Resistance: Overcoming Multiple Myeloma Drug Resistance by Inhibiting the Proteasome There are many difficult hurdles to overcome in the treatment of multiple myeloma, but one of the most important is a phenomenon called drug resistance. The International Myeloma Foundation (IMF) and Millennium Pharmaceuticals, Inc., of Cambridge, MA, the developer of VELCADE® (bortezomib) for Injection, are collaborating on a national medical education program designed for oncology nurses. Atiprimod: A New Drug Candidate in Early-Stage Development for Myeloma Atiprimod has a very interesting history, providing yet another example of a drug candidate that begins its story as a potential treatment for a wholly different disease indication. IMF Kicks Off 2004 Seminars with Florida Retreat In talking with first-time participants as well as those who had attended IMF seminars previously, it is very evident that no matter how many of these wonderful weekends one has been to, there is always new, pertinent information available. Winter 2003/2004 Volume 5, Issue 9 PDF AVAILABLE
2004 Research Grants Awarded to the Best Six of the world's most promising clinical investigators have been chosen to receive prestigious 2004 Brian D. Novis Research Grants from the International Myeloma Foundation (IMF) in order to further their research.
ASH 2003: An Avalanche of New Information The huge number of presentations at the American Society of Hematology Meetings (ASH), December 4th – 9th 2003 in San Diego capped a truly momentous year for myeloma research and new drug development. It’s that emotional time of year again, when we reflect back on the past year, sometimes with tears for what we’ve lost, sometimes with smiles for what we’ve achieved and for the sweet memories of people who have touched our lives. Advocacy Update: Congress Adjourns Thanks to the persistent work of Sen. Kay Bailey Hutchison (R-TX), the conferees to the Labor, Health and Human Services, and Education appropriations bill approved $500,000 to help support the IMF’s Bank On A Cure program. October 2003 Volume 5, Issue 8 PDF AVAILABLE Ask the Expert: The use of DOXIL® in multiple myeloma An interview with Mohamad Hussein, M.D., Director of the Myeloma Research Program at the Cleveland Clinic Taussig Cancer Center in Cleveland, Ohio. Myeloma at the Movies Lending Library The IMF has set up a video lending library of a variety of presentations and question and answer sessions.
Saluting an Incredible Human Being: Rochester, Minnesota is perhaps best known as the home of the Mayo Clinic. Most people to whom myeloma is not unknown also know that Rochester is home to Dr. Robert A. Kyle. The IMF Visits Italy and France Under the auspices of the IMF, IMF Scientific Advisors and distinguished Professors Mario Boccadoro and Jean-Luc Harousseau held the first ever IMF Patient & Family Seminars in their respective countries. Myeloma Patients and Oncology Nurses to Benefit from IMF/Millennium Collaboration The IMF and Millennium Pharmaceuticals have agreed to collaborate on a medical education initiative for oncology nurses nationally which will also benefit multiple myeloma patients in their care. It’s Your Attitude... It’s Your Choice Tom Bay, Ph.D. has asked audiences over and over again to answer the following questions: Whose life is it? Who’s responsible for it? What do you plan on doing about it? And last question… When? Early studies indicate targeted radioactive drug may expand treatment options for myeloma The studies involve the drug Quadramet, one of a new class of drugs that target radiation directly to bone and spare the rest of the body from exposure. Veterans, Agent Orange, Multiple Myeloma, and VA Benefits Veterans with MM who were exposed to Agent Orange (AO) are potentially eligible for a vast array of Department of Veterans Affairs (VA) benefits. NOTE: This article was updated on July 18, 2012.
Ask the Expert: One of the most common symptoms that lead patients with multiple myeloma to first seek medical attention is bone pain. This pain is caused by the destruction of bone material induced by myeloma cells within the center of the bone. IMF Support Group Leader Retreat Forty support group leaders, co-leaders, representatives, and IMF staff participated in the fourth annual IMF Support Group Leader Retreat, held June 27-29 at Duke University in Durham, North Carolina. The retreat lived up to the expectations of reg The Good, the Bad, and the Ugly of Cancer Public Policy On the one hand, the state of the science of cancer research and patient care is the brightest it has ever been. On the other hand, the politics and policy impacting the cancer world seem to be moving in the exact opposite direction. IMFer Profile: Terry Herman Shares Her Story I had an average life. I've always thought I was extremely healthy. I exercised, took all the right vitamins and antioxidants, and ate all the right foods. I used to laugh because my husband Howie was always running to the doctor, always thinking tha Scientific Advisor Profile: Meet New Members of the IMF Scientific Advisory Board The International Myeloma Foundation is pleased to welcome Drs. Fonseca, Gibson, Shimizu, and Westin to its distinguished Board of Scientific Advisors. She's Banking on Finding a Cure IMF President Susie Novis was profiled in the Leader's and Success section of the Investor's Business Daily. June 2003 Volume 5, Issue 6 PDF AVAILABLE Profile Interview: Julian Adams, Ph.D. The doctor who discovered VelcadeTM, talks to Myeloma Today UK. For those not involved with Myeloma, the name Little Rock Arkansas evokes memories – good or bad – of President Clinton. For those of us who live in the Myeloma world, it means one thing: Dr. Bart Barlogie and his team at the center there. Life Lessons from a Politician In the rotunda of the Salt Lake City courthouse, a life-size bronze statue of Governor Scott Matheson comes striding out to meet you, its hand extended. It captures the energy Scott Matheson had in life. He was an extraordinary man. At 53 years young, and at the pinnacle of my 25-year public relations career, I was struck by multiple myeloma....I took hold of myself and decided to go to any length to get healthy. Overview of the IXth International Workshop on Multiple Myeloma, the International Prognostic Index, and Bank On A Curetm February 2003 Volume 5, Issue 5 PDF AVAILABLE Report from the Los Angeles IMF Patient & Family Interactive Seminar
Winter 2002/2003 Volume 5, Issue 4 The beginning of a new year is always exciting. It’s a fresh start a clean slate — anything is possible. More than ever, I hear myeloma experts and researchers say that they believe we are on the brink of making myeloma a chronic disease. Can cure be Ribbon of Hope — Making a World of Difference As The Unknown Patient and his Unknown spouse dragged their luggage onto the shuttle to Washington DC, there was much to celebrate. His battle with myeloma was approaching its thirteenth year and for reasons far from Unknown, he was still going stron
Did You Know? Vaccination can help reduce the risk of some infections in individuals with multiple myeloma.
Did You Know? Almost everyone values the gift of health. By making small dietary changes you can reap rewards all year round. Research Progress Report: Dr. Ivan Van Riet A striking feature of myeloma cells concerns their tendency to reside in the bone marrow compartment during the main course of the disease evolution. The microenvironment provides the appropriate signals for growth and survival of the tumor cells. Si Myeloma Center Spotlight: University of Arkansas for Medical Sciences Comprehensive Molecular Management of Multiple Myeloma Special Edition - June 2002 Volume 4, Issue 11 PDF AVAILABLE OVAC 2002 Advocacy Day Senate Hearing: Oral Testimony of Susie Novis
April 2002 Volume 4, Issue 10 THE IMPORTANCE OF KNOWING POTENTIAL OUTCOME: Role for the new International Prognostic Index (IPI)[Now known as the International Staging System] Winter 2001/2002 Volume 4, Issue 8 PDF AVAILABLE Excerpts from Acceptance Speeches at Cirque de la Vie
It’s hard to believe that this year’s Ribbon of Hope-Making a World of Difference 11th Anniversary Gala has come and gone, raising close to $400,000! |
print
back to top